Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CICLOPIROX vs ABELCET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability, leading to leakage of intracellular ions and cell death. The lipid complex formulation (ABELCET) alters pharmacokinetics to reduce nephrotoxicity while retaining antifungal activity.
Topical treatment of tinea pedis, tinea cruris, tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis,Treatment of seborrheic dermatitis of the scalp,Treatment of cutaneous candidiasis (moniliasis) due to Candida albicans,Treatment of onychomycosis of fingernails and toenails due to Trichophyton rubrum,Off-label: Treatment of tinea versicolor, vaginal candidiasis, and superficial dermatophyte infections
Invasive fungal infections refractory to amphotericin B deoxycholate or in patients intolerant to that formulation,Aspergillosis,Candidiasis,Cryptococcosis,Blastomycosis,Histoplasmosis,Coccidioidomycosis,Zygomycosis,Fungal sinusitis,Empiric therapy in febrile neutropenic patients (off-label),Visceral leishmaniasis (off-label)
Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).
5 mg/kg IV once daily infused over 2-2.5 hours. For aspergillosis, duration is typically 2-4 weeks total.
Terminal elimination half-life: 1.7-3.0 hours in healthy individuals; prolonged in hepatic impairment
Terminal elimination half-life is approximately 120–180 hours (mean ~153 h) in adults with normal renal and hepatic function. This long half-life reflects slow redistribution from tissues and supports once-daily dosing after a loading regimen.
Minimal systemic absorption following topical application. The small absorbed fraction is primarily metabolized via glucuronidation and oxidation. Unchanged drug and metabolites are excreted renally and fecally. Specific hepatic enzymes involved are not well characterized.
Amphotericin B is not significantly metabolized in humans; it is eliminated primarily via biliary excretion with negligible renal metabolism.
Renal: approximately 70-80% of the absorbed dose as unchanged drug and glucuronide conjugates; biliary/fecal: ~20-30%
Renal excretion is minimal (<1% unchanged drug); the primary route of elimination is via the hepatobiliary system, with the majority of the dose recovered in feces as unchanged drug and metabolites. Biliary/fecal elimination accounts for >90% of clearance.
94-98% bound to plasma proteins, primarily albumin
More than 99% bound to plasma proteins, primarily to albumin and lipoproteins (e.g., LDL and HDL).
1.2-2.0 L/kg, indicating extensive tissue distribution
Volume of distribution is approximately 0.5–1.0 L/kg, indicating extensive tissue distribution (e.g., liver, spleen, lung, kidney) with limited penetration into cerebrospinal fluid and vitreous humor.
Topical: minimal systemic absorption (<1-5% of applied dose); oral: not formulated for systemic use
Not applicable; only administered intravenously. Oral bioavailability is negligible (less than 5%) due to poor gastrointestinal absorption and degradation in the GI tract.
No specific dose adjustments are recommended; systemic absorption is minimal (<1.3%) with topical application. For oral use (not available in the US), no data for renal impairment.
No dosage adjustment required, but renal function should be monitored; consider dose adjustment if Cr Cl < 30 m L/min or if significant nephrotoxicity occurs (e.g., doubling of serum creatinine).
No dose adjustments needed for topical use due to negligible systemic absorption. No data for oral formulations.
No specific adjustment; use with caution in severe hepatic impairment.
Ciclopirox 1% cream: Approved for children ≥10 years with tinea pedis or tinea corporis; apply twice daily for 2 weeks. Ciclopirox 8% nail lacquer: Not recommended in children <12 years. Ciclopirox 1% shampoo: Not established in children <16 years.
Same dosing as adults (5 mg/kg/day IV); safety and efficacy established.
No specific dose adjustments; topical use has minimal systemic absorption. Consider skin thinning and increased risk of irritation in elderly; use caution with prolonged application.
No specific adjustment, but monitor renal function and electrolyte balance due to higher risk of toxicity.
None currently listed in FDA labeling.
WARNING: Should be used primarily for treatment of progressive, potentially life-threatening fungal infections in patients intolerant to conventional amphotericin B deoxycholate or whose infection is refractory to that formulation. Not interchangeable with other amphotericin B products. Verify correct product prior to administration. Administer by intravenous infusion only.
For external use only; avoid contact with eyes and mucous membranes,If irritation or sensitivity develops, discontinue treatment,Not for intravaginal or ophthalmic use,Use in diabetic patients may require additional monitoring for nail infections,Keep away from heat and open flame (ciclopirox solution contains alcohol)
Nephrotoxicity: monitor renal function closely; may cause azotemia, hypokalemia, hypomagnesemia,Hypersensitivity reactions: anaphylaxis, bronchospasm, flushing, hypotension,Infusion-related reactions: fever, chills, rigors, headache, nausea, vomiting,Cardiotoxicity: arrhythmias, cardiac arrest (especially during rapid infusion),Hepatotoxicity: elevated liver enzymes, bilirubin,Hematologic toxicity: anemia, thrombocytopenia, leukopenia,Electrolyte disturbances: hypokalemia, hypomagnesemia, hyponatremia,Pulmonary toxicity: dyspnea, respiratory failure (rare),Prior to infusion: premedicate with antipyretics, antihistamines, and corticosteroids to reduce infusion reactions
Hypersensitivity to ciclopirox or any component of the formulation
Hypersensitivity to amphotericin B or any component of the formulation,Concurrent administration with other nephrotoxic drugs (e.g., cyclosporine, tacrolimus, aminoglycosides) unless benefit outweighs risk,Severe pre-existing renal impairment (relative contraindication; use only if no alternative)
No significant food interactions have been reported with topical ciclopirox. For oral ciclopirox (not available in the US), food may affect absorption; consult prescribing information.
No known food interactions. Maintain adequate hydration.
Topical ciclopirox has minimal systemic absorption ( < 1.5%) and is generally considered low risk. Animal studies with high doses have shown fetal toxicity, but no teratogenicity in rats or rabbits. For topical use, there is no evidence of teratogenicity in humans. However, sufficient data are lacking for first trimester risk. The drug should be used during pregnancy only if clearly needed, with caution primarily in first trimester.
Pregnancy Category B. Animal studies with amphotericin B deoxycholate have shown no evidence of fetal harm. There are no adequate and well-controlled studies in pregnant women. However, systemic fungal infections pose significant maternal and fetal risk if untreated. Use only if clearly needed.
It is unknown if ciclopirox is excreted in human milk. Due to low systemic absorption after topical application, the amount ingested by a nursing infant is likely negligible. Use with caution on small areas and avoid application to breast. M/P ratio not established.
It is not known whether amphotericin B is excreted in human milk. Because many drugs are excreted in human milk and due to the potential for adverse effects in nursing infants, the decision to discontinue nursing or discontinue the drug should be made, taking into account the importance of the drug to the mother. M/P ratio unknown.
No pharmacokinetic changes requiring dose adjustment have been reported for topical ciclopirox. Systemic absorption is minimal and pregnancy-induced changes in skin permeability or clearance are not expected to alter systemic exposure significantly. Standard topical dosing (apply twice daily to affected areas) is appropriate.
No specific dosing adjustments are recommended for pregnancy. However, given the potential for renal impairment and electrolyte disturbances, close monitoring is warranted. Dose adjustments are primarily based on renal function, which may be altered in pregnancy.
Apply topical ciclopirox once or twice daily, covering the lesion and a 1 cm margin of normal skin. For nail infections, file away loose nail material before applying lacquer. Avoid occlusive dressings unless directed. Treatment duration for tinea pedis is 2 weeks; for tinea corporis/cruris, 2-4 weeks. For onychomycosis, treatment may require 48 weeks or until nail replacement.
Monitor renal function and electrolytes closely; premedicate with diphenhydramine and acetaminophen to reduce infusion-related reactions; do not mix with saline or other electrolytes; administer via in-line filter (5 micron) only; ensure adequate hydration to prevent nephrotoxicity.
Wash hands before and after applying the medication.,Apply a thin layer to the affected area and rub in gently.,Do not use on open wounds, or in eyes, mouth, or vagina.,For nail lacquer, apply daily over the entire nail plate and to the underside of the nail tip.,Avoid nail polish or artificial nails during treatment.,Complete the full course even if symptoms improve.,Notify your doctor if irritation or allergic reaction occurs.
This medication is given intravenously and may cause fever, chills, or rigors during infusion.,Report any breathing difficulty, chest pain, or severe reaction immediately.,You may receive pre-medications to reduce side effects.,Stay well hydrated unless instructed otherwise.,Blood tests will be required to monitor kidney function and electrolytes.
"Combining ciclopirox, an antifungal agent, with benidipine, a calcium channel blocker, may result in increased toxicity or reduced therapeutic efficacy. Benidipine is metabolized via CYP3A4; ciclopirox can inhibit CYP3A4, potentially raising benidipine plasma concentrations and causing hypotension, dizziness, or peripheral edema. Additionally, ciclopirox may have additive cardiodepressant effects, leading to bradycardia or worsening heart failure in susceptible patients."
"Co-administration of Ciclopirox and Eperisone may lead to additive antagonism of normal muscle tone and coordination due to concurrent central nervous system depression. Ciclopirox, primarily used for dermatological conditions, has noted sedative effects from systemic absorption, while Eperisone centrally acts as a muscle relaxant with sedative properties. The combined use can potentiate drowsiness, dizziness, and impaired psychomotor function, increasing the risk of falls and accidents."
"Losartan, an angiotensin II receptor blocker, and ciclopirox, a topical antifungal, are not expected to have a clinically significant pharmacokinetic interaction. Ciclopirox is minimally absorbed through the skin (<0.01% of applied dose) and undergoes hepatic glucuronidation and renal excretion. Losartan is metabolized primarily by CYP2C9 and CYP3A4 to its active metabolite. The baseline statement suggests a theoretical inhibition of ciclopirox metabolism by losartan, but given ciclopirox's negligible systemic exposure after topical use and different metabolic pathways, this interaction is unlikely to produce adverse clinical outcomes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CICLOPIROX vs ABELCET, answered by our medical review team.
CICLOPIROX is a Antifungal that works by Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.. ABELCET is a Polyene antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability, leading to leakage of intracellular ions and cell death. The lipid complex formulation (ABELCET) alters pharmacokinetics to reduce nephrotoxicity while retaining antifungal activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CICLOPIROX and ABELCET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CICLOPIROX is: Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).. The standard adult dose of ABELCET is: 5 mg/kg IV once daily infused over 2-2.5 hours. For aspergillosis, duration is typically 2-4 weeks total.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CICLOPIROX and ABELCET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CICLOPIROX is classified as Category A/B. Topical ciclopirox has minimal systemic absorption ( < 1.5%) and is generally considered low risk. Animal studies with high doses have shown fetal toxicity, but no teratogenicity i. ABELCET is classified as Category C. Pregnancy Category B. Animal studies with amphotericin B deoxycholate have shown no evidence of fetal harm. There are no adequate and well-controlled studies in pregnant women. How. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.